1140-P: Health Care Professional (HCP) and Patient Perspectives on the Impact of an Autonomous AI in a Federally Qualified Health Center (FQHC)

Abstract

Introduction and Objective: Diabetic eye disease can lead to blindness, yet only 50% of people with diabetes report having an eye exam for diabetes (EED). FDA-cleared autonomous AI solutions are emerging as a point-of-care option for the EED. We assessed health care professional (HCP) (provider and operator) and, separately, patient perspectives about using autonomous AI for EED (LumineticsCore, Digital Diagnostics Inc, Coralville, IA), at Zufall Health Center (ZHC), a FQHC. Methods: Surveys were anonymously completed by HCPs immediately prior to implementation of autonomous AI for EED (April 2021) and again afterwards (August 2023); patient surveys were anonymously completed between May 2022 and June 2023 immediately following an autonomous AI EED. Pre/Post descriptive statistics were generated. Results: 13/13 HCPs completed surveys prior to implementation and 8/17 completed surveys following implementation; 131/519 patients completed surveys, a 25.2% response rate. Prior to implementation HCPs cited time (46.2%), space (61.5%), and additional workload (30.8%) as expected common challenges in adoption. Following implementation, 87.5% of HCPs “strongly agreed” with recommending autonomous AI EED as a routine part of diabetes care. 46/131 (35.1%) of patients reported having never received an annual EED prior to the autonomous AI. The majority of patients, 115/127 (90.6%), “agreed” or “strongly agreed” with the statement “Overall, I am very satisfied with the autonomous AI EED I received.” Conclusion: Despite EEDs being an evidence-based recommendation (American Diabetes Association and American Academy of Ophthalmology) and a quality measure (National Committee for Quality Assurance), more than a third of ZHC patients reported never having received an EED. Integrating an autonomous AI for EED at point-of-care can ensure increased access, reducing the risk of vision loss in underserved populations. Disclosure M. Castro: None. D. Bishop: None. D. Weitzman: Employee; Digital Diagnostics. R. Ramirez: None.

Ähnliche Arbeiten